REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021
Read about the phase II clinical trial of Stemchymal, where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with SCA.
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
16 February 2021
Read Axion BioSystems announcement of Bioserve Biotechnologies Pvt Ltd (REPROCELL) as the new distributor of its Maestro systems and consumables in India.
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020
Find out more about REPROCELL's announcement that they will launch a new service to generate individual specific induced pluripotent stem cells (iPSC's)
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
10 December 2020
Find out about how REPROCELL, an industry leader in the use of human biospecimens for medical research has achieved VIP supplier status on scientist.com
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
17 August 2020
REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
16 July 2020
Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
15 July 2020
Find out more about REPROCELL's launch of StemRNA Entero human iPSC-derived intestinal epithelial cells. a more clinically relevant alternative to Caco2 cells.
REPROCELL’s Personal iPS Service is Launched in Japan
15 July 2020
Read more about REPROCELL's exciting new launch of its Personal iPS service, allowing customers to store cells for future regenerative medicine treatment.
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
13 July 2020
Find out why eTheRNA's mRNA vaccine may offer a long-term solution to COVID in our interview with REPROCELL's CEO.
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
28 February 2020
REPROCELL is pleased to announce that the first patient has been registered and been administrated at for the Phase II clinical trial of Stemchyma.
Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
13 February 2020
Read the announcement that REPROCELL Europe’s Prof Stefan Przyborski will giving the keynote address on 3D cell culture at the SMi Annual Conference London
Patients with IBD absorb drugs differently from healthy individuals
16 January 2020
Read about how a recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals.
REPROCELL can now predict oral bioavailability in fresh IBD tissue
14 January 2020
REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal resections from IBD donors.
Early understanding of pharmacology and genomics can improve precision medicine strategies
23 December 2019
REPROCELL announce the successful publication of a novel study in pharmacology and genomics to improve strategies for precision medicine.
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
13 November 2019
Lantern Pharma, a biotech leveraging A.I. and machine learning, has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.
Appointment of New Distributor in Thailand
04 November 2019
Read about the REPROCELL groups distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
25 October 2019
REPROCELL will apply the funding towards the development of stem cell banking for iPSCs and NSCs derived from various neurodegenerative disease patients.
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
25 September 2019
This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons.
PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor
28 August 2019
Axion BioSystems has announced REPROCELL as the new distributor of its Maestro products in Japan. Read the official Press Release at reprocell.com
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
22 August 2019
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.